EVLO Insider Trading Activity and SEC Form 4 Filings
EVLO insider trading summary
No open-market insider purchases or sales of Evelo Biosciences, Inc. (EVLO) have been reported on SEC Form 4 in the past 12 months.
Latest EVLO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 8, 2023 | Marella Thorell | Chief Financial Officer | Sell | $598 (1,811 @ $0.33) |
| Nov 8, 2023 | Duncan McHale | Chief Medical Officer | Sell | $1K (3,103 @ $0.33) |
| Nov 8, 2023 | Mark Bodmer | CSO, President of R&D | Sell | $1K (3,163 @ $0.33) |
| Nov 8, 2023 | Simba Gill | President & CEO | Sell | $57 (172 @ $0.33) |
| Nov 2, 2023 | Duncan McHale | Chief Medical Officer | Sell | $2K (6,854 @ $0.33) |
| Nov 2, 2023 | Marella Thorell | Chief Financial Officer | Sell | $1K (3,999 @ $0.33) |
| Nov 2, 2023 | Mark Bodmer | CSO, President of R&D | Sell | $2K (6,854 @ $0.33) |
| Sep 28, 2023 | Simba Gill | President & CEO | Sell | $8K (1,996 @ $3.94) |
| Aug 8, 2023 | Simba Gill | President & CEO | Sell | $3K (342 @ $9.51) |
| Aug 8, 2023 | Marella Thorell | Chief Financial Officer | Sell | $19K (2,004 @ $9.51) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.